Compensation for weight-loss research studies that touch compounded tirzepatide or semaglutide depends almost entirely on which drug a volunteer is currently taking. Studies that pay for time and travel generally want participants on brand-name Wegovy, Zepbound, or Mounjaro — not a compounded or generic version — because sponsors need a known, FDA-approved dose to measure against. That distinction exists because compounded versions of these drugs sit in a different regulatory category than the brand-name originals, and that category has been shrinking. Understanding why helps explain why so many studies screen compounded users out before pay or eligibility even come up.
Official resources:
- Check eligibility on ClinicalTrials.gov’s official study page — Use this page to check the study’s participation requirements.
- Check eligibility on Uab’s official study page — Use this page to check the study’s participation requirements.
Table of Contents
- Why Compounded GLP-1 Drugs Keep Getting Study Doors Closed
- Which Studies Explicitly Exclude Compounded Users
- Where Compounded Users Might Still Qualify
- What Pay Looks Like Across Study Types
- A Quick Eligibility Checklist Before Applying
- Frequently Asked Questions
Why Compounded GLP-1 Drugs Keep Getting Study Doors Closed
Compounding pharmacies could legally make copies of tirzepatide and semaglutide only while the FDA listed the brand-name versions as being in shortage. The FDA declared the Eli Lilly tirzepatide shortage resolved in December 2024 and the Novo Nordisk semaglutide shortage resolved in February 2025, which started wind-down deadlines that curtailed compounding pharmacies' ability to make copies of these drugs. The agency then moved to make that restriction permanent.
On May 1, 2026, the FDA proposed permanently keeping semaglutide, tirzepatide, and liraglutide off the approved list of substances pharmacies can legally compound, with the public comment period closing July 30, 2026 and no final rule issued as of this writing. Compounding pharmacies challenged the restrictions in court and lost preliminary-injunction requests in March and April 2025. Their appeal reached the Fifth Circuit Court of Appeals, which heard oral arguments on March 30, 2026, with no ruling reported yet. Until that appeal resolves, the restrictions on compounded versions stand, which is part of why research sponsors treat compounded users as a separate, often excluded, group.
Which Studies Explicitly Exclude Compounded Users
Some study listings state their exclusion in plain language, which makes screening easy for a prospective volunteer. RCR Clinical's weight-management study, protocol META0036, explicitly disqualifies anyone currently taking compounded or generic semaglutide or tirzepatide, limiting eligibility to users of brand-name Wegovy or Zepbound. UAB's AMAZE 9 study, recruiting as of September 2026, applies a related but broader bar.
It enrolls adults aged 18 to 69 with a BMI of 30 or higher, no type 1 or type 2 diabetes, and no prescription or compounded GLP-1 use within the year before screening, since the trial is testing an investigational drug called Zenagamtide against a placebo and needs participants without recent GLP-1 exposure of any kind. A third pattern shows up across the industry generally rather than in one named study: many obesity-drug trials listed on ClinicalTrials.gov require a washout period of 90 to 180 days from any prior GLP-1 receptor agonist before screening. That standard, visible in protocol NCT04251156's semaglutide-obesity trial, in practice excludes current compounded-drug users from most sponsor-run studies, since few volunteers can go three to six months without their medication just to qualify.
Where Compounded Users Might Still Qualify
Not every paid study specifies a brand requirement. Nucleus Network's "Elevate Study" in Minneapolis recruits generally healthy adults currently taking semaglutide or tirzepatide and pays $50 to $500 per day for study time, but the listing does not state whether compounded versions satisfy that requirement. A volunteer taking a compounded version should confirm directly with the study coordinator before assuming it counts, since silence on the point is not the same as approval.
This gap matters because telehealth companies selling compounded GLP-1 products have drawn direct FDA scrutiny over how they describe their products. On March 3, 2026, the FDA sent 30 warning letters to telehealth companies over misleading marketing claims about compounded GLP-1 weight-loss products. That enforcement activity gives study coordinators reason to ask pointed questions about dosage, source, and formulation before clearing a compounded user for any study that didn't spell out the rule in advance.
What Pay Looks Like Across Study Types
Pay structures vary by what the study is actually testing, not just by eligibility rules. Nucleus Network's model pays a daily rate of $50 to $500 for time spent on site, which reflects the burden of inpatient or intensive monitoring common in early-phase pharmacology studies. UAB's REIMAGINE 4 study, which compares the drug CagriSema to tirzepatide (sold as Mounjaro) in adults with type 2 diabetes, takes a different approach: it charges participants nothing and states that compensation for time and travel may be available, rather than quoting a fixed daily rate.
AMAZE 9 similarly offers compensation for study visits without publishing a specific dollar figure. The practical takeaway is that a volunteer should ask two separate questions before enrolling: what the study pays, and what it costs. A study that charges nothing and might reimburse travel is a different financial proposition than one quoting a per-day rate for inpatient time, even when both are legitimate and well-run.
A Quick Eligibility Checklist Before Applying
Reviewing a few points before contacting a study coordinator can save a wasted screening call:.
- Confirm whether the study names a brand-specific requirement (Wegovy, Zepbound, Mounjaro) or simply says "semaglutide" or "tirzepatide" without specifying source.
- Ask directly whether a compounded or generic version of the drug meets the stated requirement, since most listings do not address this explicitly.
- Check for a washout period — some trials, like those following the NCT04251156 pattern, require 90 to 180 days off any GLP-1 drug before screening, which rules out anyone currently on a compounded version.
- Note whether the study pays a flat daily rate (as with Nucleus Network) or only offers to reimburse time and travel (as with UAB's REIMAGINE 4 and AMAZE 9), since these represent very different compensation models.
- If the compounded product was obtained through a telehealth provider, be ready to describe its exact formulation and source, given the FDA's March 2026 warning letters targeting misleading marketing in that channel.
Frequently Asked Questions
Does taking a compounded version of semaglutide or tirzepatide disqualify someone from every paid study?
Not every study states a brand requirement, but many do, and industry-standard washout periods of 90 to 180 days from any GLP-1 drug exclude most current compounded users from sponsor-run trials.
Why do so many studies specifically require brand-name drugs instead of compounded versions?
Sponsors need participants on a known, FDA-approved dose and formulation to measure results against, and compounded versions aren't standardized the same way across pharmacies.
Is it still legal to get compounded semaglutide or tirzepatide in 2026?
The FDA proposed permanently barring both drugs from the approved compounding list in May 2026, and a compounding-industry court appeal was argued before the Fifth Circuit in March 2026 with no ruling yet, so the legal status remains unsettled.
